Global Technology Report

Group B Streptococcus Market Report 2040: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Minervax ApS

 Breaking News
  • No posts were found

Group B Streptococcus Market Report 2040: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Minervax ApS

April 19
08:59 2024
Group B Streptococcus Market Report 2040: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Minervax ApS
The Group B Streptococcus Market Forecast report offers an in-depth understanding of the Group B Streptococcus, historical and forecasted epidemiology as well as the Group B Streptococcus market trends in the 7MM.

DelveInsight’s “Group B Streptococcus Market Insights, Epidemiology, and Market Forecast-2040″ report offers an in-depth understanding of the Group B Streptococcus, historical and forecasted epidemiology as well as the Group B Streptococcus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Group B Streptococcus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Group B Streptococcus Market Forecast

 

Some of the key facts of the Group B Streptococcus Market Report: 

  • The Group B Streptococcus market size was valued approximately USD 194 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2040)
  • In April 2023, MinervaX commenced a Phase I clinical trial for its novel GBS vaccine, aiming to evaluate its safety and effectiveness in the older adult demographic affected by Group B Streptococcus (GBS). This trial, conducted at the Centre for Vaccinology (CEVAC) in Ghent, Belgium, will focus on assessing the vaccine’s impact through the administration of two doses to individuals aged 55 to 75, both with and without pre-existing medical conditions.
  • In 2022, the United States dominated the market among the seven major markets, with a value of USD 139 million. Meanwhile, the combined market value of the European Union Four (EU4) and the United Kingdom (UK) amounted to USD 43 million during the same period.
  • According to DelveInsight’s projections, there were approximately 226,722 reported cases of GBS across the 7MM (Seven Major Markets), and these numbers are expected to notably increase by the conclusion of 2040.
  • In the Seven Major Markets (7MM), the European Union Four (EU4) and the United Kingdom (UK) together represented 20% of the overall reported cases of GBS.
  • According to DelveInsight’s analysis, there were approximately 151,932 reported cases of GBS infection in the United States in 2022. These numbers are anticipated to increase over the projected period.
  • The analysis indicates that there were approximately 33,633 cases of type-specific incident invasive GBS infections and 118,299 cases of non-invasive GBS infections in the United States.
  • The market is eagerly anticipating the release of two potential products, GBS-NN/NN2 by MinervaX and Multivalent GBS 6 by Pfizer. These entities have the potential to significantly impact the reduction of newborn and maternal mortality rates among the affected population, addressing a crucial global public health concern.
  • Key Group B Streptococcus Companies: Pfizer, Minervax ApS, and others
  • Key Group B Streptococcus Therapies: GBS-NN/NN2, GBS 6, and others
  • The Group B Streptococcus epidemiology based on gender analyzed that non-invasive GBS infection has a higher incidence than invasive Group B Streptococcus
  • The Group B Streptococcus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Group B Streptococcus pipeline products will significantly revolutionize the Group B Streptococcus market dynamics.

 

Group B Streptococcus Overview

Group B Streptococcus (GBS) is a type of bacteria commonly found in the intestines, rectum, and genital tract of humans. While it typically doesn’t cause harm in healthy adults, it can lead to serious infections in certain populations, particularly newborns, pregnant women, the elderly, and individuals with weakened immune systems.

 

Get a Free sample for the Group B Streptococcus Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/group-b-streptococcus-gbs-market

 

Group B Streptococcus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2040. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Group B Streptococcus Epidemiology Segmentation:

The Group B Streptococcus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Group B Streptococcus
  • Prevalent Cases of Group B Streptococcus by severity
  • Gender-specific Prevalence of Group B Streptococcus
  • Diagnosed Cases of Episodic and Chronic Group B Streptococcus

 

Download the report to understand which factors are driving Group B Streptococcus epidemiology trends @ Group B Streptococcus Epidemiology Forecast

 

Group B Streptococcus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Group B Streptococcus market or expected to get launched during the study period. The analysis covers Group B Streptococcus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Group B Streptococcus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Group B Streptococcus Therapies and Key Companies

  • GBS-NN/NN2: Minervax ApS
  • GBS 6: Pfizer

 

Discover more about therapies set to grab major Group B Streptococcus market share @ Group B Streptococcus Treatment Landscape

 

Scope of the Group B Streptococcus Market Report

  • Study Period: 2019–2040
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Group B Streptococcus Companies: Pfizer, Minervax ApS, and others
  • Key Group B Streptococcus Therapies: GBS-NN/NN2, GBS 6, and others
  • Group B Streptococcus Therapeutic Assessment: Group B Streptococcus current marketed and Group B Streptococcus emerging therapies
  • Group B Streptococcus Market Dynamics: Group B Streptococcus market drivers and Group B Streptococcus market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Group B Streptococcus Unmet Needs, KOL’s views, Analyst’s views, Group B Streptococcus Market Access and Reimbursement 

 

To know more about Group B Streptococcus companies working in the treatment market, visit @ Group B Streptococcus Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Group B Streptococcus Market Report Introduction

2. Executive Summary for Group B Streptococcus

3. SWOT analysis of Group B Streptococcus

4. Group B Streptococcus Patient Share (%) Overview at a Glance

5. Group B Streptococcus Market Overview at a Glance

6. Group B Streptococcus Disease Background and Overview

7. Group B Streptococcus Epidemiology and Patient Population

8. Country-Specific Patient Population of Group B Streptococcus 

9. Group B Streptococcus Current Treatment and Medical Practices

10. Group B Streptococcus Unmet Needs

11. Group B Streptococcus Emerging Therapies

12. Group B Streptococcus Market Outlook

13. Country-Wise Group B Streptococcus Market Analysis (2019–2032)

14. Group B Streptococcus Market Access and Reimbursement of Therapies

15. Group B Streptococcus Market Drivers

16. Group B Streptococcus Market Barriers

17.  Group B Streptococcus Appendix

18. Group B Streptococcus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories